The initial report of the US Expanded Access Program for fenfluramine indicates that those with Dravet syndrome treated with fenfluramine (Fintepla; Zogenix) have clinically meaningful responses similar to that observed in clinical trials.
from Front page feed https://ift.tt/2WfD9ox
from Front page feed https://ift.tt/2WfD9ox
Comments
Post a Comment